Skip to main content

Truvian Closes $105M Series C Financing Round

NEW YORK – Truvian announced on Wednesday that it has closed a $105 million Series C financing round, bringing the total amount the company has raised to date to more than $150 million. 

The round was led by TYH Ventures, Glen Tullman at 7wireVentures, and Wittington Ventures, with additional investors including GreatPoint Ventures, General Catalyst, DNS Capital, and Wasson Enterprise. 

The funding will be used to help Truvian prepare submission of its point-of-care blood testing platform to the US Food and Drug Administration for regulatory clearance. It will also help scale the company's team to commercialize of the automated benchtop platform, Truvian said in a statement. 

The platform combines clinical chemistries, immunoassays, and hematology tests in one device and can perform "all standard blood tests ordered during a routine checkup on site," the company said. The comprehensive wellness panel will cover the most commonly ordered diagnostic tests, namely a lipid panel, metabolic panel, and complete blood cell count.

Truvian also announced a variety of new executive and board appointments, including Jay Srinivasan, former VP of automation and informatics at Abbott, as chief product officer.